Clinical translation of epigenetics in cancer

eN-CORe - A report on the second workshop

Arthur Zelent, Kevin Petrie, Reuben Lotan, Samuel Waxman, Steven D. Gore

Research output: Contribution to journalArticle

Abstract

Recent advances in understanding the role that epigenetics plays in cancer pathogenesis and understanding the mechanisms through which these processes regulate gene expression have stimulated considerable interest in developing clinically viable antineoplastic agents that target enzymatic components of transcriptional regulatory complexes responsible for the establishment of pathologic epigenetic modifications that lead to deregulated gene expression in cancer. In January 2003, a workshop was held in Baltimore to discuss the therapeutic potential of several agents that can modify chromatin structure. A follow-up meeting on "Clinical Translation of Epigenetics in Cancer" was held in Charleston, SC, in January 2005. The aim of this workshop was to assess the progress that has been made over the past 2 years in bringing effective therapeutic protocols that use agents capable of reverting pathologic epigenetic changes into the clinic. The meeting was attended by ∼ 70 investigators and included formal presentations, panel group discussions, and two breakout sessions that addressed targeted therapies in hematologic and solid tumors. The aim of this article is to summarize topics discussed at this workshop and highlight conclusions as to the immediate and long-term future of epigenetic therapy in cancer.

Original languageEnglish (US)
Pages (from-to)1810-1819
Number of pages10
JournalMolecular Cancer Therapeutics
Volume4
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Epigenomics
Education
Neoplasms
Gene Expression
Baltimore
Therapeutic Uses
Antineoplastic Agents
Chromatin
Therapeutics
Research Personnel

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Clinical translation of epigenetics in cancer : eN-CORe - A report on the second workshop. / Zelent, Arthur; Petrie, Kevin; Lotan, Reuben; Waxman, Samuel; Gore, Steven D.

In: Molecular Cancer Therapeutics, Vol. 4, No. 11, 11.2005, p. 1810-1819.

Research output: Contribution to journalArticle

Zelent, Arthur ; Petrie, Kevin ; Lotan, Reuben ; Waxman, Samuel ; Gore, Steven D. / Clinical translation of epigenetics in cancer : eN-CORe - A report on the second workshop. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 11. pp. 1810-1819.
@article{61fed17ab8c94aec9ea0249a09f707c4,
title = "Clinical translation of epigenetics in cancer: eN-CORe - A report on the second workshop",
abstract = "Recent advances in understanding the role that epigenetics plays in cancer pathogenesis and understanding the mechanisms through which these processes regulate gene expression have stimulated considerable interest in developing clinically viable antineoplastic agents that target enzymatic components of transcriptional regulatory complexes responsible for the establishment of pathologic epigenetic modifications that lead to deregulated gene expression in cancer. In January 2003, a workshop was held in Baltimore to discuss the therapeutic potential of several agents that can modify chromatin structure. A follow-up meeting on {"}Clinical Translation of Epigenetics in Cancer{"} was held in Charleston, SC, in January 2005. The aim of this workshop was to assess the progress that has been made over the past 2 years in bringing effective therapeutic protocols that use agents capable of reverting pathologic epigenetic changes into the clinic. The meeting was attended by ∼ 70 investigators and included formal presentations, panel group discussions, and two breakout sessions that addressed targeted therapies in hematologic and solid tumors. The aim of this article is to summarize topics discussed at this workshop and highlight conclusions as to the immediate and long-term future of epigenetic therapy in cancer.",
author = "Arthur Zelent and Kevin Petrie and Reuben Lotan and Samuel Waxman and Gore, {Steven D.}",
year = "2005",
month = "11",
doi = "10.1158/1535-7163.MCT-05-0230",
language = "English (US)",
volume = "4",
pages = "1810--1819",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Clinical translation of epigenetics in cancer

T2 - eN-CORe - A report on the second workshop

AU - Zelent, Arthur

AU - Petrie, Kevin

AU - Lotan, Reuben

AU - Waxman, Samuel

AU - Gore, Steven D.

PY - 2005/11

Y1 - 2005/11

N2 - Recent advances in understanding the role that epigenetics plays in cancer pathogenesis and understanding the mechanisms through which these processes regulate gene expression have stimulated considerable interest in developing clinically viable antineoplastic agents that target enzymatic components of transcriptional regulatory complexes responsible for the establishment of pathologic epigenetic modifications that lead to deregulated gene expression in cancer. In January 2003, a workshop was held in Baltimore to discuss the therapeutic potential of several agents that can modify chromatin structure. A follow-up meeting on "Clinical Translation of Epigenetics in Cancer" was held in Charleston, SC, in January 2005. The aim of this workshop was to assess the progress that has been made over the past 2 years in bringing effective therapeutic protocols that use agents capable of reverting pathologic epigenetic changes into the clinic. The meeting was attended by ∼ 70 investigators and included formal presentations, panel group discussions, and two breakout sessions that addressed targeted therapies in hematologic and solid tumors. The aim of this article is to summarize topics discussed at this workshop and highlight conclusions as to the immediate and long-term future of epigenetic therapy in cancer.

AB - Recent advances in understanding the role that epigenetics plays in cancer pathogenesis and understanding the mechanisms through which these processes regulate gene expression have stimulated considerable interest in developing clinically viable antineoplastic agents that target enzymatic components of transcriptional regulatory complexes responsible for the establishment of pathologic epigenetic modifications that lead to deregulated gene expression in cancer. In January 2003, a workshop was held in Baltimore to discuss the therapeutic potential of several agents that can modify chromatin structure. A follow-up meeting on "Clinical Translation of Epigenetics in Cancer" was held in Charleston, SC, in January 2005. The aim of this workshop was to assess the progress that has been made over the past 2 years in bringing effective therapeutic protocols that use agents capable of reverting pathologic epigenetic changes into the clinic. The meeting was attended by ∼ 70 investigators and included formal presentations, panel group discussions, and two breakout sessions that addressed targeted therapies in hematologic and solid tumors. The aim of this article is to summarize topics discussed at this workshop and highlight conclusions as to the immediate and long-term future of epigenetic therapy in cancer.

UR - http://www.scopus.com/inward/record.url?scp=28044463368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044463368&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0230

DO - 10.1158/1535-7163.MCT-05-0230

M3 - Article

VL - 4

SP - 1810

EP - 1819

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -